TY - JOUR
KW - Covid-19
KW - adjuvent therapy
KW - breast cancer
KW - endocrine therapy < hormone therapy
KW - pandemic
KW - Prostate cancer
AU - N. Barclay
AU - M. Català
AU - A. Jödicke
AU - D. Prieto-Alhambra
AU - D. Newby
AU - A. Delmestri
AU - W . Y. Man
AU - Serrano À
AU - M. Moncusí
AD - Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Windmill Road, Oxford OX3 7LD, UK.
Department of Medical Informatics, Erasmus Medical Center University, Rotterdam, The Netherlands.
Institut Català d'Oncologia, Hospital Universitari Dr Josep Trueta, Girona, Catalonia, Spain.
AN - 38832300
BT - Ther Adv Med Oncol
C2 - PMC11146008
DO - 10.1177/17588359241253115
DP - NLM
ET - 2024/06/04
LA - eng
N1 - 1758-8359
Barclay, Nicola L
Orcid: 0000-0002-6500-9909
Català, Marti
Jödicke, Annika M
Prieto-Alhambra, Daniel
Newby, Danielle
Delmestri, Antonella
Man, Wai Yi
Serrano, Àlvar Roselló
Moncusí, Marta Pineda
OPTIMA Consortium
Journal Article
England
Ther Adv Med Oncol. 2024 Jun 2;16:17588359241253115. doi: 10.1177/17588359241253115. eCollection 2024.
PY - 2024
SN - 1758-8340 (Print)1758-8340
EP - 17588359241253115
T2 - Ther Adv Med Oncol
TI - Collateral effects of the COVID-19 pandemic on endocrine treatments for breast and prostate cancer in the UK: a cohort study
VL - 16
ER -